Apyx Medical Corporation (NASDAQ:APYX) Given Average Rating of “Moderate Buy” by Brokerages

Apyx Medical Corporation (NASDAQ:APYX) has earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $6.6667.

Several equities research analysts have issued reports on APYX shares. Citizens Jmp raised shares of Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research note on Wednesday, November 12th. Roth Mkm began coverage on shares of Apyx Medical in a research report on Monday, December 15th. They issued a “buy” rating and a $6.00 target price for the company. Wall Street Zen raised shares of Apyx Medical to a “hold” rating in a research note on Saturday, November 22nd. BTIG Research upgraded shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, December 29th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in APYX. Kingsview Wealth Management LLC increased its holdings in Apyx Medical by 9.4% in the 2nd quarter. Kingsview Wealth Management LLC now owns 191,597 shares of the company’s stock valued at $431,000 after purchasing an additional 16,502 shares during the last quarter. Fisher Asset Management LLC purchased a new position in shares of Apyx Medical during the second quarter worth $34,000. Nantahala Capital Management LLC grew its stake in shares of Apyx Medical by 2.5% in the second quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock valued at $7,511,000 after buying an additional 80,000 shares in the last quarter. Osaic Holdings Inc. purchased a new stake in shares of Apyx Medical in the 2nd quarter valued at $50,000. Finally, Salem Investment Counselors Inc. purchased a new stake in shares of Apyx Medical in the 3rd quarter valued at $97,000. 55.33% of the stock is currently owned by hedge funds and other institutional investors.

Apyx Medical Price Performance

Shares of APYX opened at $3.45 on Wednesday. The business’s 50-day moving average is $3.74 and its two-hundred day moving average is $3.31. The company has a market capitalization of $131.93 million, a P/E ratio of -9.58 and a beta of 1.61. Apyx Medical has a fifty-two week low of $0.76 and a fifty-two week high of $4.50. The company has a debt-to-equity ratio of 5.69, a quick ratio of 3.61 and a current ratio of 4.44.

Apyx Medical (NASDAQ:APYX) last posted its earnings results on Tuesday, March 10th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. The firm had revenue of $19.16 million during the quarter, compared to analyst estimates of $19.12 million. Apyx Medical had a negative net margin of 30.35% and a negative return on equity of 151.01%. Research analysts predict that Apyx Medical will post -0.68 earnings per share for the current year.

Trending Headlines about Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q4 results: Apyx reported EPS of ($0.03) vs. consensus ($0.06) and revenue of $19.16M (vs. $19.12M expected) — the beat supports near‑term sentiment and shows improving top‑line execution. Apyx Medical Corp (APYX) Q4 2025 Earnings Call Highlights
• Positive Sentiment: FY‑2026 revenue guidance raised: management guided revenue to $57.5M–$58.5M, above the consensus ~$55.9M — this upward guidance is the main constructive catalyst for the stock today. Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Growth driver: the company reiterated a 9%–11% revenue growth target for 2026 and cited acceleration of the AYON Body Contouring System launch — investors may view product momentum as evidence that guidance is achievable. Apyx Medical outlines 9%–11% revenue growth target for 2026 as AYON launch
• Neutral Sentiment: Analyst/press coverage: earnings breakdowns and summaries (Benzinga, MarketBeat coverage and the company’s press release/conference call transcript) are available for investors to review management commentary and model impacts. Earnings Breakdown: Apyx Medical Q4 Company Press Release / Call Transcript
• Negative Sentiment: Profitability remains a concern: Apyx reported a negative net margin (~‑30%) and very negative ROE (~‑151%), indicating continued losses and execution risks despite revenue growth. Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Short interest moved higher in late February (173,573 shares, +22.3% vs. prior period; ~0.5% of float, ~2.7 days to cover). Elevated shorting can add volatility and represents a potential headwind if negative sentiment persists. (Data point reported in filings/market feeds.)
• Neutral Sentiment: Data anomalies on short interest in early March (entries showing 0 shares) appear inconsistent — treat those figures as unreliable until exchanges/custodians reconcile the reports.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.